As Biogen INC (BIIB) Share Value Declined, Saratoga Research & Investment Management Lifted Holding

December 8, 2017 - By Hazel Jackson

Investors sentiment decreased to 0.88 in 2017 Q2. Its down 0.16, from 1.04 in 2017Q1. It is negative, as 81 investors sold BIIB shares while 321 reduced holdings. 78 funds opened positions while 277 raised stakes. 180.66 million shares or 1.01% less from 182.50 million shares in 2017Q1 were reported. Eqis Management Incorporated has invested 0.06% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Montrusco Bolton Invs Inc, a Quebec – Canada-based fund reported 38,703 shares. 578,425 are held by Swedbank. The Washington-based Garde Capital has invested 0.11% in Biogen Inc. (NASDAQ:BIIB). Moreover, Glg Limited Liability Company has 0.48% invested in Biogen Inc. (NASDAQ:BIIB) for 29,021 shares. Independent Portfolio Consultants holds 454 shares. Tributary Cap Mgmt Limited Company has invested 0.04% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Synovus accumulated 24,925 shares. Acadian Asset Mgmt Ltd Liability Corp holds 0.01% or 11,923 shares in its portfolio. Legal And General Group Incorporated Public Limited Liability Co, United Kingdom-based fund reported 1.07 million shares. Commonwealth Natl Bank Of holds 0.05% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 19,576 shares. Pioneer Mngmt, a Massachusetts-based fund reported 26,290 shares. Comml Bank Of Hawaii holds 0.03% or 1,295 shares in its portfolio. Nippon Life Glob Americas holds 0.55% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 23,570 shares. Hudson Bay Capital Mngmt Limited Partnership owns 35,000 shares for 0.19% of their portfolio.

Saratoga Research & Investment Management increased its stake in Biogen Inc (BIIB) by 8.98% based on its latest 2017Q2 regulatory filing with the SEC. Saratoga Research & Investment Management bought 11,340 shares as the company’s stock declined 13.45% while stock markets rallied. The institutional investor held 137,562 shares of the biological products (no diagnostic substances) company at the end of 2017Q2, valued at $37.33 million, up from 126,222 at the end of the previous reported quarter. Saratoga Research & Investment Management who had been investing in Biogen Inc for a number of months, seems to be bullish on the $67.58B market cap company. The stock increased 1.56% or $4.91 during the last trading session, reaching $319.57. About 987,076 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since December 8, 2016 and is uptrending. It has underperformed by 11.76% the S&P500.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Investorplace.com which released: “Bet on Biogen Inc for Easy Profits Into the New Year” on November 21, 2017, also Seekingalpha.com with their article: “Another Threat For Biogen’s MS Franchise” published on November 15, 2017, Fool.com published: “The case for Gilead Sciences” on November 18, 2017. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Streetinsider.com and their article: “Biogen Inc.” published on November 21, 2017 as well as Finance.Yahoo.com‘s news article titled: “Biogen Inc (BIIB): Immense Growth Potential?” with publication date: November 23, 2017.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Among 31 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 21 have Buy rating, 0 Sell and 10 Hold. Therefore 68% are positive. Biogen Idec Inc. had 92 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Tuesday, July 11. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Outperform” rating by Wells Fargo on Friday, December 4. The stock has “Outperform” rating by BMO Capital Markets on Wednesday, October 25. Jefferies maintained the stock with “Hold” rating in Wednesday, October 5 report. The stock of Biogen Inc. (NASDAQ:BIIB) has “Market Perform” rating given on Thursday, March 16 by Leerink Swann. The company was upgraded on Tuesday, October 17 by Stifel Nicolaus. The rating was maintained by H.C. Wainwright on Thursday, October 22 with “Buy”. The stock has “Buy” rating by Jefferies on Wednesday, September 9. The firm has “Buy” rating by Cowen & Co given on Tuesday, October 24. The rating was downgraded by Citigroup to “Neutral” on Tuesday, June 7.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.